High income (World Bank) vs Oman: Pneumococcal conjugate second or third-dose vaccines (PCVc)
High income (World Bank)
87.0%
in 2025
Oman
99.0%
in 2025
High income (World Bank) rank
2nd
Oman rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- High income (World Bank)
- Oman
How they compare
Oman currently reports 99.0% against 87.0% in High income (World Bank), a difference of 12.0%.
That makes Oman's figure about 1.1 times High income (World Bank)'s.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was High income (World Bank) ahead.
High income (World Bank) ranks 2nd and Oman ranks 1st of 11 groups.
Oman has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | High income (World Bank) | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 38.5% | 48.0% | 9.5% | Oman |
| 2010s | 73.3% | 98.8% | 25.5% | Oman |
| 2020s | 87.3% | 98.7% | 11.3% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), High income (World Bank) or Oman?
- Oman, at 99.0% against 87.0% in High income (World Bank) as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between High income (World Bank) and Oman?
- 12.0%, with Oman ahead.
- How many years of comparable data are there for High income (World Bank) and Oman?
- 18 years are reported by both, from 2008 to 2025.
- How do High income (World Bank) and Oman rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- High income (World Bank) ranks 2nd and Oman ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.